Retatrutide: The Triple Agonist Redefining Weight Loss Research
The incretin-based therapeutic landscape has evolved rapidly over the past decade, moving from single GLP-1 receptor agonists to dual agonists like tirzepatide. Now, a new molecule is pushing the boundaries even further. Retatrutide (LY3437943), developed by Eli Lilly, is the first triple hormone receptor agonist to reach late-stage clinical trials — simultaneously targeting GLP-1, GIP, and glucagon receptors. Early phase 2 data suggest it may produce weight loss results that surpass anything previously observed in pharmacological obesity research.
How Retatrutide Works: Three Receptors, One Molecule
Retatrutide is a single peptide that activates three distinct metabolic receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple agonism creates a synergistic metabolic effect that goes beyond what any single- or dual-agonist can achieve alone.
GLP-1 receptor activation suppresses appetite, slows gastric emptying, and enhances insulin secretion — the same mechanism driving semaglutide (Ozempic/Wegovy). GIP receptor activation, also leveraged by tirzepatide (Mounjaro/Zepbound), appears to potentiate the effects of GLP-1 and may independently influence fat metabolism and insulin sensitivity.
The novel addition is glucagon receptor agonism. Glucagon has traditionally been viewed with caution in diabetes contexts due to its glucose-raising effects, but it plays a powerful role in energy expenditure, hepatic lipid oxidation, and thermogenesis. By incorporating controlled glucagon activity into the peptide's pharmacology, retatrutide may address metabolic dysfunction at a level that purely incretin-based therapies cannot reach. Coskun et al., 2022 published the preclinical characterization of LY3437943, demonstrating that the molecule produced superior weight loss and metabolic improvements in animal models compared to dual agonists.
Phase 2 Clinical Results: Unprecedented Efficacy
The landmark phase 2 trial of retatrutide, published in The New England Journal of Medicine, generated significant attention across the metabolic research community. Jastreboff et al., 2023 enrolled 338 adults with obesity (BMI ≥30, or ≥27 with comorbidities) and randomized them to receive subcutaneous retatrutide at various doses or placebo over 48 weeks.
The results were striking:
These numbers represent a substantial leap beyond existing therapies. For comparison, semaglutide 2.4 mg (Wegovy) produced approximately 14.9% weight loss at 68 weeks in the STEP 1 trial (Wilding et al., 2021), while tirzepatide 15 mg (Zepbound) achieved up to 20.9% at 72 weeks in the SURMOUNT-1 trial (Jastreboff et al., 2022). Retatrutide appears to reach higher efficacy in a shorter timeframe, though direct head-to-head comparisons have not yet been conducted.
Metabolic Effects Beyond the Scale
Weight loss alone does not capture the full scope of retatrutide's metabolic effects. In the phase 2 data, researchers observed significant improvements in multiple cardiometabolic risk markers.
Participants treated with retatrutide showed reductions in waist circumference, fasting glucose, HbA1c, triglycerides, and blood pressure. A separate analysis of the trial's type 2 diabetes cohort (Rosenstock et al., 202301053-X)) found that retatrutide reduced HbA1c by up to 2.02 percentage points at the 12 mg dose, with 71% of participants achieving an HbA1c below 5.7% — essentially non-diabetic glycemic levels.
The glucagon receptor component may be particularly relevant for liver health. Glucagon agonism promotes hepatic fat oxidation, and preclinical data suggest retatrutide could significantly reduce liver fat content. A sub-study using MRI-based proton density fat fraction (MRI-PDFF) found that participants on the 12 mg dose experienced a liver fat reduction exceeding 80% from baseline, with many achieving normalization below the 5% fat threshold used to define metabolic dysfunction-associated steatotic liver disease (MASLD). These findings were presented alongside the main trial results and have generated particular excitement given the lack of approved pharmacotherapies specifically targeting MASLD (Sanyal et al., 2024).
Safety Profile and Tolerability
The side effect profile of retatrutide is broadly consistent with the GLP-1 receptor agonist class, though the additional receptor targets introduce unique considerations.
The most commonly reported adverse events in the phase 2 trial were gastrointestinal in nature:
Most GI events were mild to moderate and occurred primarily during dose escalation, consistent with what has been observed with semaglutide and tirzepatide. Gradual dose titration appears to mitigate the severity and frequency of these effects.
Heart rate increases were observed across dose groups, a known pharmacological effect of GLP-1 receptor agonism that warrants ongoing cardiovascular monitoring in larger trials. Importantly, no cases of pancreatitis or medullary thyroid carcinoma were reported, though the phase 2 trial was not powered to detect rare events. Long-term safety data from phase 3 trials will be essential to fully characterize the risk-benefit profile, particularly regarding the glucagon receptor's potential effects on hepatic glucose output in susceptible populations.
Phase 3 Program: The TRIUMPH Trials
Eli Lilly has launched a comprehensive phase 3 clinical program called TRIUMPH, designed to evaluate retatrutide across multiple patient populations. The program includes trials in obesity, type 2 diabetes, obstructive sleep apnea, MASLD, and cardiovascular risk reduction (ClinicalTrials.gov: NCT05929066).
Key TRIUMPH trials include:
These trials are expected to enroll thousands of participants and provide the large-scale efficacy and safety data needed for regulatory submission. Results from the first TRIUMPH studies are anticipated in 2025–2026, with potential FDA approval following shortly after if outcomes align with phase 2 signals.
How Retatrutide Compares to Existing Therapies
Understanding where retatrutide fits relative to semaglutide and tirzepatide requires acknowledging the limitations of cross-trial comparisons, but the trajectory of incretin-based drug development is clear:
| Parameter | Semaglutide 2.4 mg | Tirzepatide 15 mg | Retatrutide 12 mg |
|---|---|---|---|
| Receptor Targets | GLP-1 | GLP-1 + GIP | GLP-1 + GIP + Glucagon |
| Peak Weight Loss | ~14.9% (68 wks) | ~20.9% (72 wks) | ~24.2% (48 wks) |
| HbA1c Reduction | ~1.5% | ~2.1% | ~2.0% |
| Liver Fat Reduction | Moderate | Significant | Potentially greatest |
| Phase | Approved | Approved | Phase 3 |
The addition of each receptor target appears to amplify metabolic outcomes, though this also increases pharmacological complexity. Retatrutide's glucagon component is particularly differentiated, as it may drive energy expenditure and hepatic fat clearance beyond what GLP-1/GIP dual agonism alone can achieve (Finan et al., 2015).
Open Questions in the Research
Despite the remarkable early data, several critical questions remain unanswered. The durability of weight loss after treatment discontinuation has not been studied for retatrutide, though data from semaglutide suggest significant weight regain occurs once therapy is stopped (Wilding et al., 2022). Whether retatrutide's broader receptor profile confers any advantage in weight maintenance remains unknown.
The long-term cardiovascular safety and efficacy profile also requires clarification. While semaglutide has demonstrated cardiovascular risk reduction in the SELECT trial (Lincoff et al., 2023), no comparable outcome data yet exist for retatrutide. The TRIUMPH-3 trial is designed to address this gap.